연구개에서 발생한 골수외성 형질세포종 : 증례보고

(1)

Ⅰ. INTRODUCTION

A plasmacytoma is a rare malignancy composed of plasma cells.

¹⁾

Plasmacytomas are unifocal, monoclonal, neoplastic proliferations that usually arise within bone;

however, an extramedullary plasmacytoma (EMP) can occur in soft tissues. The majority of primary EMPs occur in the head and neck region, especially in the upper respiratory tract and oral cavity. It is believed that EMPs ultimately develop into multiple myeloma (MM). We present a case

report of a 52-year-old female with an EMP.

Ⅱ. CASE REPORT

A 52-year-old female was referred to the Department of Oral and Maxillofacial Surgery for evaluation of soft palate swelling. The patient had no pertinent medical history.

The initial workup included a complete blood cell count (CBC), electrolyte panel, and imaging studies. Laboratory results showed no signs of anemia, hypercalcemia, or renal insufficiency. Upon clinical examination, a 1.5 x 1 cm, reddish, non-tender mass with telangiectasia was found near the midline of the soft palate (Fig. 1A, 2A). There were no signs of cervical lymphadenopathy.

연구개에서 발생한 골수외성 형질세포종: 증례보고

권도현¹⁾, 명훈^1,2)*

서울대학교 치의학 대학원 구강악안면외과학교실

¹⁾

, 치의학연구소

²⁾

<Abstract>

Case Report: Extramedullary Plasmacytoma of Soft Palate

Dohyun Kwon

¹⁾

,Hoon Myoung

^1,2)

*

Department of Oral and Maxillofacial Surgery

¹⁾

, School of Dentistry, Seoul National University, Seoul, Korea Dental Research Institute

²⁾

, Seoul National University, Seoul, Korea

Extramedullary plasmacytomas (EMPs) are rare soft tissue malignant neoplasms composed of plasma cells. They are sometimes found in soft tissues. The majority of primary EMPs occur in the head and neck region, especially in the upper respiratory tract and oral cavity. We present a case of a 52-year-old female with an EMP. The patient’s initial chief complaint was swelling of the soft palate.

An excisional biopsy was performed under general anesthesia. Final pathologic diagnosis was EMP of the soft palate with partial involvement of the resection margin. In order to exclude the possibility of multiple myeloma, a bone marrow exam with chromosomal study was completed. The patient was also referred to the Department of Radiation Oncology for postoperative radiation therapy (PORT); however, the patient refused to undergo PORT. The patient is currently under close observation for signs and symptoms of recurrence or metastases through regular follow-up visits and imaging studies.

Key words : Extramedullary plasmacytoma, EMP, Oral cavity, Soft palate

Korean Journal of Oral and Maxillofacial Pathology 2016;40(3):000-000 ISSN:1225-1577(Print); 2384-0900(Online) Available online at http://journal.kaomp.org http://dx.doi.org/10.17779/KAOMP.2016.40.3.005

* Correspondence: Hoon Myoung, Department of Oral and Maxillofacial Surgery, Dental Research Institute, Seoul National University 101 Daehakno, Jongno-gu, Seoul 03080, Korea TEL: +82-2-2072-3059 FAX: +82-2-766-4948

E-mail: myoungh@snu.ac.kr ORCID : 0000-0001-8450-5513

(2)

Magnetic resonance (MR) imaging showed an enhancing mass with poorly demarcated radiographic margins causing bulging of the soft palate. The lesion had a hypointense T2 signal. Benign neoplasms such as a mucocele were ruled out due to the evenly distributed enhancement of the lesion. No enlarged or irregular cervical lymph nodes were found radiographically (Figs. 1B, 1C).

An excisional biopsy was performed under general anesthesia. The resected mass was 1.8 x 1.4 x 1.1 cm in size and was filled with solid whitish material (Fig. 2A, 2B).

Final pathologic diagnosis was an EMP of the soft palate with partial involvement of the resection margin.

Microscopic examination showed sheets of plasma cells with varying degrees of differentiation in a monomorphic plasmacytoma pattern (Figs. 3 A, B, C, D). Immunohistochemical studies confirmed the monoclonality of the plasma cells.

Immunohistochemistry with antibodies to kappa light chain was negative, but that with lambda chain antibodies was positive (Figs. 3 E, F). Ki-67 staining was present in fewer than 1% of cells. Extensive plasma cell proliferation was

Fig. 1. A) Preoperative intraoral clinical photograph.

B) T1-weighted magnetic resonance imaging showing heterogenous lesion with unclear margin. – axial view C) T1-weighted magnetic resonance imaging showing heterogenous lesion with unclear margin. – coronal view

Fig. 2. A) Perioperative clinical photograph. B) Postoperative photograph of main mass.

(3)

Fig. 3. Microscopic examination of the mass.

A) (H&E staining, x12)

B) Stained section demonstrates monomorphic pattern of plasmacytoma (H&E staining, x100).

C) Sheets of plasma cells showing varying degrees of differentiation (H&E staining, x200).

D) Plasma cells show round eccentric nuclei (H&E staining, x400).

E) Immunohistochemistry with antibodies to kappa light chain. Kappa(-), x200.

F) Immunohistochemistry with antibodies to lambda light chain. Lambda(+), x200.

(4)

observed and is a major indicator of a plasmacytoma. The resection margin, however, showed partial involvement of the tumor cells.

Postoperative and follow-up MR images showed no definite residual or recurrent lesion in the oral cavity and no significant cervical lymphadenopathy. Postoperative PET-CT imaging showed mild hypermetabolism in the left soft palate, which is most likely a postoperative change (Fig. 4A, 4B).

After pathologic diagnosis of malignancy, the patient was admitted to the Department of Oral and Maxillofacial Surgery for a formal workup. The patient was then referred to the Department of Radiation Oncology for consultation regarding postoperative radiation therapy (PORT). In order to rule out the possibility of multiple myeloma, a bone marrow exam with a chromosomal study was performed.

The bone marrow exam was negative, thus excluding multiple myeloma. Radiation oncology recommended PORT for definitive care; however, the patient refused. The patient

is currently under close observation for signs and symptoms of recurrence or metastases through regular follow-up visits and imaging studies. 1-year follow up MRI showed no definite residual or recurred lesion in the oral cavity and no significant cervical lymphadenopathy.

Ⅲ. DISCUSSION

Extramedullary plasmactomas are rare soft tissue malignant neoplasms composed of plasma cells.

¹⁾

EMPs account for approximately 1% to 2% of malignancies. They occur at a rate of 3.5/100,000 per year.

^2-4)

Plasmacytomas present as multiple myeloma, solitary plasmacytoma of bone (SBP), or EMP.

^5-7)

These tumors usually present clinically without evidence of tumor elsewhere. Although extraosseous plasma cell infiltrates are found in more than 2/3 of patients with multiple myeloma at autopsy, EMP is rarely (5%) the presenting manifestation.

^8-11)

SMP differs from multiple myeloma in its

Fig. 4. A) Postoperative clinical photo

B) Postoperative PET-CT image showing mild hypermetabolism in the left soft palate, which was likely a postoperative change.

(5)

lack of plasma cell infiltration in a random bone marrow biopsy. Unlike multiple myeloma, SMP patients usually show no signs of hypercalcemia, anemia or renal failure.

¹⁴⁾

Patients with plasmacytoma of the oral cavity show symptoms like jaw pain, toothache, swelling, paresthesia, mobility of teeth, hemorrhage, and pathologic fracture of the involved bone. In this case, the patient complained of no symptoms other than swelling.

^5,12,13)

Radiographically, EMP can erode bone and might not be easily distinguishable from SBP.

¹⁵⁾

The lesion can be seen as a well-defined, unilocular radiolucency with no evidence of sclerotic borders or as a ragged radiolucency similar in appearance to multiple myeloma.

¹⁴⁾

EMP shows histopathologic features identical to those of multiple myeloma, such as sheets of plasma cells showing different degrees of differentiation. Immunohistochemically, EMP seems to show lack or marked decrease of immunoreactivity for antibodies directed against cyclin D1 and CD56, compared to solitary plasmacytoma of bone.

¹⁴⁾

Dissemination or progression to multiple myeloma occurs in up to 85% of patients in solitary plasmacytoma of bone.

However, extramedullary plasmacytomas mostly remain well localized. Thus, EMP has a much better prognosis.

Only 30% of patients with EMP progress to multiple myeloma, and 70% have a 10-year disease-free period after treatment.

¹⁴⁾

Local recurrence occurs in 6 - 10% of cases that have had adequate initial treatment.

^7,17,18)

The reported 5-year overall survival rates for patients range from 40 – 85%.

^17,19,20)

The treatment option for solitary extramedullary plasmacytoma is radiotherapy at a dose of 4 to 50 Gy over a 4-week period.

^21,22)

If solitary extramedullary plasmacytoma was resected completely as part of the diagnosis, the role of adjuvant radiotherapy is less clear. Small lesions can be cured with surgery alone, and if there is no suspicion of residual disease, adjuvant radiotherapy is not indicated.

Adjuvant chemotherapy does not appear to improve the relapse rate or increase disease-free survival.

²³⁾

Investigation of patients with suspected plasma cell tumors should include a full workup to rule out multiple myeloma. Urinalysis for Bence-Jones protein, serum protein electrophoresis, serum electrophoresis, bilateral bone marrow examinations, and a skeletal survey are all essential to the diagnostic workup. Only when other systemic diseases have been ruled out can the diagnosis of SEP be entertained.

¹⁶⁾

Ⅳ. CONCLUSION

The pathologic exam in the present case resulted in a final diagnosis of extramedullary plasmacytoma with partial tumor involvement at the resection margin. Postoperative radiotherapy was recommended by radiation oncology;

however, the patient refused further treatment. The patient is currently under close observation for signs and symptoms of recurrence or metastases through regular follow-up visits and imaging studies.

Although uncommon, EMPs are found in the palatal region. This clinically benign-appearing entity has the possibility of evolving into multiple myeloma. The diagnostic process entails a full multiple myeloma workup including urinalysis, serum analysis, and an invasive spinal marrow exam. Thus, when encountering a soft tissue mass in an unusual location, a thorough radiographic exam should precede surgical removal of the lesion, and the possibility of systemic involvement should be considered.

When in doubt, prompt referral to an oral and maxillofacial

surgery specialist or oncologist is strongly recommended for

proper care and long-term follow-up.

(6)

Ⅳ. REFERENCES

1. Kapadia SB, UMA Desai, Vincent SC: Extramedullary Plasmacytoma of the Head and Neck: A CLINICOPATHOLOGIC STUDY OF 20 CASES. Medicine (Baltimore) 1982;61:317-329.

2. Mendenhall WM, Charles MM, Nancy PM: Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol 2003;24:395-399.

3. Bolek TW, Robert BM, Nancy PM: Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 1996;36:329-333.

4. Nofsinger YC: Head and neck manifestations of plasma cell neoplasms. The laryngoscope 107.6 (1997):741-746.

5. Pisano JJ: Plasmacytoma of the oral cavity and jaws: a clinicopathologic study of 13 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:265-271.

6. Parker S: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.

7. Batsakis JG: Plasma cell tumors of the head and neck. Ann Otol Rhinol Laryngol 1983;92:311-313.

8. Churg J, AJ Gordon: Multiple myeloma; lesions of the extra-osseous hematopoietic system. Am J Clin Pathol 1950;20:934-945.

9. Pasmantier MW, Azar HA: Extraskeletal spread in multiple plasma cell myeloma: A review of 57 autopsied cases.

Cancer 1969;23:167–174.

10. Edwards GA, Zbigniew A: Zawadzki. Extraosseous lesions in plasma cell myeloma: a report of six cases. Am J Med 1967;43:194-205.

11. Kapadia SB: Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 1980;59:380.

12. Ozdemir R: Plasmacytoma of the hard palate. J Craniofac Surg 2005;16:164-169.

13. Epstein JB, NJS Voss, P Stevenson-Moore: Maxillofacial manifestations of multiple myeloma: An unusual case and review of the literature. Oral Surg Oral Med Oral Pathol 1984;57:267-271.

14. Neville BW, Damm DD, Allen CM: Oral and maxillofacial pathology. Philadelphia Saunders, 2008, 606-607.

15. Majumdar SU, Raghavan NSJ: Solitary plasmacytoma and extramedullary plasmacytoma of the paranasal sinuses and soft palate. J Laryngol Otol 2002;116: 962-965.

16. Wax MK, KJ Yun, Rawhi AO: Extramedullary plasmacytomas of the head and neck. Otolaryngol Head Neck Surg 1993;109:877-885.

17. Knowling MA, Andrew RH, Daniel EB: Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1983;1:255-262.

18. Wiltshaw E: The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 1976;55:217-238.

19. Avilés A, Huerta-Guzmán J, Delgado S, et al: Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 1996;14:111.

20. Dimopoulos MA, Goldstein J, Fuller L: Curability of solitary bone plasmacytoma. J Clin Oncol 1992;10:587.

21. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P et al:

Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys 2006;64:1013.